drugset / Trial / NCT02254369
Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to assess the safety and tolerability of single oral doses of GC021109 when administered to healthy adult subjects.
Timeline
- Start
- 2014-09
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC021109 | Unknown | 0.0014 mg/kg | Oral |
| Subject | GC021109 | Unknown | 0.014 mg/kg | Oral |
| Subject | GC021109 | Unknown | 0.14 mg/kg | Oral |
| Subject | GC021109 | Unknown | 1.4 mg/kg | Oral |
| Subject | GC021109 | Unknown | 4.2 mg/kg | Oral |
Indications
No indication recorded.